Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP2202
- Development stage
- Phase 1
- Lead developer
- BrightPath Biotherapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
BP2202 is an investigational allogeneic cell therapy based on induced pluripotent stem cell (iPSC)-derived invariant natural killer T (iNKT) cells engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA). Designed as an off-the-shelf immunotherapy for multiple myeloma, BP2202 aims to leverage the unique tumor-targeting and immunomodulatory properties of iNKT cells, with enhanced cytotoxicity against malignant plasma cells expressing BCMA. Developed by BrightPath Biotherapeutics, BP2202 received U.S. FDA Orphan Drug Designation for the treatment of multiple myeloma in July 2025, with plans for initiation of clinical trials in the U.S.
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BP2202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP2202.